According to the 2021 Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer, the first-line treatment plan for advanced metastatic GC with Her-2 negative was strategized as follows: in the Grade I recommended plan, the combination of oxaliplatin and tegafur gimeracil oteracil potassium capsule (i.e., SOX) is classified as Class 1A. Here, ERBB2 is linked to gastric cancer.